Saxenda® (liraglutide injection) is indicated as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management in:
- Adult patients with an initial body mass index (BMI) of:1
- 30 kg/m2 or greater (obesity), or
- 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbidity (e.g., hypertension, type 2 diabetes, or dyslipidemia) and who have failed a previous weight management intervention.
- Pediatric patients aged 12 to less than 18 years with:1
- an inadequate response to reduced calorie diet and increased physical activity alone, and
- a body weight above 60 kg (132 lbs), and
- an initial body mass index (BMI) corresponding to ≥30 kg/m2 for adults (obesity) by international cut-offs
Limitations of Use:
-
Clinical efficacy and safety data from patients with BMI 27 to 29.9 kg/m2 in the presence of at least one weight-related comorbid condition (e.g., hypertension, type 2 diabetes mellitus, or dyslipidemia) are limited (N = 149).
-
The safety and effectiveness of Saxenda® in pediatric patients with type 2 diabetes have not been established.
Please consult the Product Monographor click herefor more information on:
-
Contraindications in patients with personal or family history of medullary thyroid carcinoma (MTC), Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), pregnant and breastfeeding women
-
The most serious warning and precaution regarding the risk of thyroid C-cell tumours
-
Other relevant warnings and precautions regarding combination use with other weight loss products, administration considerations; risk of increased heart rate and PR interval prolongation; use in patients with type 2 diabetes mellitus; risk of acute pancreatitis or gallbladder disease; risk of hypersensitivity and angioedema; risk of breast neoplasms; use in patients with suicidal behaviour and ideation; use in patients with recent myocardial infarction, unstable angina and congestive heart failure; use in patients with hepatic or renal insufficiency, inflammatory bowel disease or diabetic gastroparesis
-
Conditions of clinical use, adverse reactions, drug interactions and dosing instructions
The Product Monograph is also available by calling Novo Nordisk at 1-800-465-4334.
